You are here

MSC Therapy for Acute Respiratory Distress Syndrome

A new STEM CELLS Translational Medicine article from the laboratory of Ben Antebi (U.S. Army Institute of Surgical Research, San Antonio, Texas) recently sought to explore the potential of mesenchymal stem cell (MSC) therapy for acute respiratory distress syndrome (ARDS) patients. Xu et al. characterized cytokine expression in serum from ARDS subjects receiving MSCs and determined MSC function following “preconditioning” with ARDS serum. Interestingly, the results suggested that while preconditioning MSCs with serum from subjects with ARDS negatively impacts their functional properties. MSCs preconditioned with serum that was previously exposed to MSCs potentiate their regenerative function. Overall, the authors suggest “pre‐exposure” technique as a means to develop MSCs with augmented function for clinical applications.

For more, see the associated Press Release from the Stem Cells Portal "Study reveals a ‘reconditioning’ process that increases stem cells ability to treat ARDS" (